Drugs / Recombinant erythropoietin stimulating protein
Recombinant erythropoietin stimulating protein
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02356419 | Sep 2014 → Jan 2015 | chronic renal failure syndrome | Shenyang Sunshine Pharmaceutical Co., LTD. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant erythropoietin stimulating protein | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02356419 ↗ |
| Modality | Protein / enzyme biologic | “long-acting recombinant protein products” NCT02356419 ↗ |
| Route | Intravenous | “single intravenous injection” NCT02356419 ↗ |